Pharmacist-led deprescribing of cardiovascular and diabetes medication within a clinical medication review: the LeMON study (Less Medicines in Older Patients in the Netherlands), a cluster randomized controlled trial

被引:0
|
作者
Abou, Jamila [1 ]
Elders, Petra J. M. [2 ]
Huijts, Danielle [1 ]
van Marum, Rob [3 ,4 ]
Hugtenburg, Jacqueline [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Amsterdam Univ, Med Ctr, Dept Clin Pharmacol & Pharm, Amsterdam, Netherlands
[2] VU, Amsterdam UMC, Amsterdam Publ Hlth Res Inst, Dept Gen Practice, Amsterdam, Netherlands
[3] Amsterdam UMC Locat VUmc, Amsterdam Publ Hlth Res Inst, Dept Elderly Care Med, Amsterdam, Netherlands
[4] Jeroen Bosch Hosp, Dept Clin Pharmacol, Shertogenbosch, Netherlands
关键词
Frail elderly; Medication reconciliation; Medication review; Pharmacists; Polypharmacy; DRUG-RELATED PROBLEMS; COMMUNITY PHARMACIES; HOSPITAL ADMISSIONS; GENERAL-PRACTICE; BLOOD-PRESSURE; CARE; POLYPHARMACY; HYPERTENSION; ADULTS; IMPLEMENTATION;
D O I
10.1007/s11096-025-01863-w
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundDeprescribing inappropriate cardiovascular and antidiabetic medication has been shown to be feasible and safe. Healthcare providers often perceive the deprescribing of cardiovascular and antidiabetic medication as a challenge and therefore it is still not widely implemented in daily practice.AimThe aim was to assess whether training focused on conducting a deprescribing-oriented clinical medication review (CMR) results in a reduction of the inappropriate use of cardiovascular and antidiabetic medicines.MethodA cluster randomized controlled trial involving 20 community pharmacists, who conducted a clinical medication review in 10 patients. The intervention group received training on deprescribing. Patients 70 years or older with polypharmacy having a systolic blood pressure below 140 mmHg and using antihypertensive medication and/or an HbA1c level below 54 mmol/mol and using antidiabetic medication, were included. Follow-up took place within 4 weeks (T1) and after 3 months (T2). The primary outcome measure was the proportion of patients with one or more cardiovascular and antidiabetic medicine deprescribed within 3 months after the CMR (T2).ResultsA total of 71 patients in the intervention group and 69 patients in the control group were included. At T2, 32% of patients in the intervention group and 26% in the control group (OR 1.4, CI 0.65-2.82, p = 0.413) had one or more cardiovascular or antidiabetic medicines discontinued. Regarding any medication, these percentages were 51% and 36%, (OR 1.8, CI 0.92-3.56, p = 0.085) respectively.ConclusionIncreased awareness and ability of community pharmacists to deprescribe medication and use of general practitioners' data, led community pharmacists and general practitioners to successfully conduct a more deprescribing-focused CMR in daily practice. Further research is needed to assess the necessity of additional training to optimize the deprescribing of cardiovascular and antidiabetic medication.The study was registered at The Netherlands Trial Register (registration no: NL8082).ConclusionIncreased awareness and ability of community pharmacists to deprescribe medication and use of general practitioners' data, led community pharmacists and general practitioners to successfully conduct a more deprescribing-focused CMR in daily practice. Further research is needed to assess the necessity of additional training to optimize the deprescribing of cardiovascular and antidiabetic medication.The study was registered at The Netherlands Trial Register (registration no: NL8082).
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Humanistic outcomes and patient acceptance of the pharmacist-led medication review "Polymedication Check" in primary care in Switzerland: a prospective randomized controlled trial
    Messerli, Markus
    Vriends, Noortje
    Hersberger, Kurt E.
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1071 - 1078
  • [42] A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial
    Bandiera, Carole
    Cardoso, Evelina
    Locatelli, Isabella
    Zaman, Khalil
    Diciolla, Antonella
    Digklia, Antonia
    Stravodimou, Athina
    Cristina, Valerie
    Aedo-Lopez, Veronica
    Dolcan, Ana
    Sarivalasis, Apostolos
    Bouchaab, Hasna
    Pasquier, Jerome
    Dotta-Celio, Jennifer
    Peters, Solange
    Wagner, Dorothea
    Csajka, Chantal
    Schneider, Marie Paule
    PLOS ONE, 2024, 19 (06):
  • [43] A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial
    Bandiera, C.
    Cardoso, E.
    Locatelli, I.
    Zaman, K.
    Diciolla, A.
    Digklia, A.
    Stravodimou, A.
    Cristina, V.
    Aedo-Lopez, V.
    Dolcan, A. M.
    Sarivalasis, A.
    Bouchaab, H.
    Pasquier, J.
    Dotta-Celio, J.
    Peters, S.
    Wagner, A. D.
    Csajka, C.
    Schneider, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1237 - S1237
  • [44] Authors' response to the comments to "Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study"
    Abdulsalim, Suhaj
    Unnikrishnan, Mazhuvancherry Kesavan
    Manu, Mohan K.
    Alrasheedy, Alian A.
    Godman, Brian
    Morisky, Donald E.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2018, 14 (04): : 402 - 403
  • [45] Primary care pharmacist-led medication review in older adult patients in coordination with general practitioners: an observational retrospective cohorts study
    Dominguez-Berrueta, M. C. Herrero
    Munoz-Garcia, M.
    Delgado-Silveira, E.
    Martin-Aragon, S.
    Fermoso, A. Gangoso
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2024, 13
  • [46] Clinical pharmacist-led medication reconciliation supplemented with medication review in admitted patients with chronic kidney disease: a cost-benefit analysis
    Altawalbeh, Shoroq M.
    Sallam, Nahlah M.
    Al-Khatib, Minas
    Alshogran, Osama Y.
    Amer, Mohammad S. Bani
    BMJ OPEN, 2025, 15 (02):
  • [47] CLINICAL PHARMACIST-LED MEDICATION RECONCILIATION SUPPLEMENTED WITH MEDICATION REVIEW IN CHRONIC KIDNEY DISEASE ADMITTED PATIENTS: A COST-BENEFIT ANALYSIS
    Altawalbeh, S.
    Sallam, N.
    Al-Khatib, M.
    Alshogran, O.
    Bani, Amer M.
    VALUE IN HEALTH, 2024, 27 (12) : S83 - S83
  • [48] The effect of clinical pharmacist-led pharmaceutical care services on medication adherence, clinical outcomes and quality of life in patients with stroke: a randomised controlled trial
    Cengiz, Kayhan Nuri
    Midi, Ipek
    Sancar, Mesut
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025, 47 (01) : 99 - 106
  • [49] Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial
    Lenander, Cecilia
    Elfsson, Birgitta
    Danielsson, Birgitta
    Midlov, Patrik
    Hasselstrom, Jan
    SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2014, 32 (04) : 180 - 186
  • [50] The Medicines Advice Service Evaluation (MASE): a randomised controlled trial of a pharmacist-led telephone based intervention designed to improve medication adherence
    Lyons, Imogen
    Barber, Nicholas
    Raynor, David K.
    Wei, Li
    BMJ QUALITY & SAFETY, 2016, 25 (10) : 759 - 769